Annual EBIT
-$41.71 M
+$3.23 M+7.19%
December 31, 2023
Summary
- As of February 7, 2025, ONCT annual earnings before interest & taxes is -$41.71 million, with the most recent change of +$3.23 million (+7.19%) on December 31, 2023.
- During the last 3 years, ONCT annual EBIT has fallen by -$24.17 million (-137.80%).
- ONCT annual EBIT is now -376.31% below its all-time high of $15.10 million, reached on December 31, 2010.
Performance
ONCT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$8.68 M
+$182.00 K+2.05%
September 30, 2024
Summary
- As of February 7, 2025, ONCT quarterly earnings before interest & taxes is -$8.68 million, with the most recent change of +$182.00 thousand (+2.05%) on September 30, 2024.
- Over the past year, ONCT quarterly EBIT has increased by +$98.00 thousand (+1.12%).
- ONCT quarterly EBIT is now -119.61% below its all-time high of $44.27 million, reached on March 31, 2010.
Performance
ONCT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$35.96 M
+$1.71 M+4.54%
September 30, 2024
Summary
- As of February 7, 2025, ONCT TTM earnings before interest & taxes is -$35.96 million, with the most recent change of +$1.71 million (+4.54%) on September 30, 2024.
- Over the past year, ONCT TTM EBIT has increased by +$2.39 million (+6.23%).
- ONCT TTM EBIT is now -338.19% below its all-time high of $15.10 million, reached on December 31, 2010.
Performance
ONCT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ONCT EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.2% | +1.1% | +6.2% |
| 3 y3 years | -137.8% | +28.5% | +23.8% |
| 5 y5 years | -6.8% | +28.5% | +23.8% |
ONCT EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -33.0% | +7.2% | -7.4% | +28.5% | -14.6% | +23.8% |
| 5 y | 5-year | -177.7% | +7.2% | -203.4% | +28.5% | -106.5% | +23.8% |
| alltime | all time | -376.3% | +23.4% | -119.6% | +38.6% | -338.2% | +34.0% |
Oncternal Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.68 M(-2.1%) | -$35.96 M(-4.5%) |
| Jun 2024 | - | -$8.86 M(+1.0%) | -$37.67 M(-1.8%) |
| Mar 2024 | - | -$8.78 M(-8.9%) | -$38.35 M(-8.1%) |
| Dec 2023 | -$41.71 M(-7.2%) | -$9.64 M(-7.3%) | -$41.71 M(-5.2%) |
| Sep 2023 | - | -$10.39 M(+8.9%) | -$43.99 M(-2.1%) |
| Jun 2023 | - | -$9.54 M(-21.4%) | -$44.93 M(-4.8%) |
| Mar 2023 | - | -$12.14 M(+1.9%) | -$47.18 M(+5.0%) |
| Dec 2022 | -$44.95 M(+43.3%) | -$11.91 M(+5.2%) | -$44.95 M(+9.3%) |
| Sep 2022 | - | -$11.32 M(-4.0%) | -$41.11 M(+4.3%) |
| Jun 2022 | - | -$11.79 M(+19.0%) | -$39.42 M(+11.6%) |
| Mar 2022 | - | -$9.91 M(+22.7%) | -$35.32 M(+12.6%) |
| Dec 2021 | -$31.37 M(+78.8%) | -$8.08 M(-16.2%) | -$31.37 M(+20.0%) |
| Sep 2021 | - | -$9.64 M(+25.3%) | -$26.15 M(+25.1%) |
| Jun 2021 | - | -$7.69 M(+29.0%) | -$20.91 M(+11.5%) |
| Mar 2021 | - | -$5.96 M(+108.3%) | -$18.75 M(+6.9%) |
| Dec 2020 | -$17.54 M(+16.8%) | -$2.86 M(-34.9%) | -$17.54 M(-7.0%) |
| Sep 2020 | - | -$4.39 M(-20.6%) | -$18.86 M(-2.9%) |
| Jun 2020 | - | -$5.54 M(+16.5%) | -$19.42 M(+11.5%) |
| Mar 2020 | - | -$4.75 M(+13.6%) | -$17.41 M(-6.4%) |
| Dec 2019 | -$15.02 M(-61.5%) | -$4.18 M(-15.5%) | -$18.60 M(-7.0%) |
| Sep 2019 | - | -$4.95 M(+40.1%) | -$20.01 M(-19.0%) |
| Jun 2019 | - | -$3.53 M(-40.5%) | -$24.69 M(-21.2%) |
| Mar 2019 | - | -$5.94 M(+6.4%) | -$31.31 M(-19.8%) |
| Dec 2018 | -$39.06 M(+27.4%) | -$5.59 M(-42.0%) | -$39.06 M(-8.9%) |
| Sep 2018 | - | -$9.63 M(-5.2%) | -$42.87 M(+2.6%) |
| Jun 2018 | - | -$10.16 M(-25.8%) | -$41.78 M(+9.8%) |
| Mar 2018 | - | -$13.69 M(+45.6%) | -$38.06 M(+24.2%) |
| Dec 2017 | -$30.66 M(+18.2%) | -$9.40 M(+10.2%) | -$30.66 M(+9.0%) |
| Sep 2017 | - | -$8.53 M(+32.4%) | -$28.12 M(+6.0%) |
| Jun 2017 | - | -$6.45 M(+2.6%) | -$26.52 M(+1.5%) |
| Mar 2017 | - | -$6.28 M(-8.5%) | -$26.13 M(+0.8%) |
| Dec 2016 | -$25.93 M(+18.7%) | -$6.86 M(-0.9%) | -$25.93 M(+3.6%) |
| Sep 2016 | - | -$6.93 M(+14.4%) | -$25.03 M(+4.4%) |
| Jun 2016 | - | -$6.06 M(-0.5%) | -$23.96 M(+4.8%) |
| Mar 2016 | - | -$6.08 M(+2.1%) | -$22.87 M(+4.7%) |
| Dec 2015 | -$21.84 M(-28.0%) | -$5.96 M(+1.6%) | -$21.84 M(+2.3%) |
| Sep 2015 | - | -$5.86 M(+18.2%) | -$21.34 M(+4.4%) |
| Jun 2015 | - | -$4.96 M(-1.9%) | -$20.43 M(-22.7%) |
| Mar 2015 | - | -$5.06 M(-7.3%) | -$26.42 M(-12.9%) |
| Dec 2014 | -$30.35 M(-30.4%) | -$5.46 M(+10.1%) | -$30.35 M(-10.9%) |
| Sep 2014 | - | -$4.96 M(-54.7%) | -$34.07 M(-10.5%) |
| Jun 2014 | - | -$10.95 M(+21.8%) | -$38.07 M(-4.7%) |
| Mar 2014 | - | -$8.99 M(-2.1%) | -$39.95 M(-8.4%) |
| Dec 2013 | -$43.60 M | -$9.18 M(+2.4%) | -$43.60 M(-7.9%) |
| Sep 2013 | - | -$8.96 M(-30.1%) | -$47.33 M(-7.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$12.82 M(+1.5%) | -$51.13 M(+2.4%) |
| Mar 2013 | - | -$12.64 M(-2.1%) | -$49.95 M(+0.4%) |
| Dec 2012 | -$49.73 M(+38.5%) | -$12.91 M(+1.1%) | -$49.73 M(+1.9%) |
| Sep 2012 | - | -$12.76 M(+9.7%) | -$48.83 M(+4.0%) |
| Jun 2012 | - | -$11.64 M(-6.3%) | -$46.95 M(+2.1%) |
| Mar 2012 | - | -$12.42 M(+3.5%) | -$46.00 M(+26.1%) |
| Dec 2011 | -$35.90 M(-337.8%) | -$12.00 M(+10.2%) | -$36.47 M(+13.8%) |
| Sep 2011 | - | -$10.89 M(+2.0%) | -$32.06 M(+7.8%) |
| Jun 2011 | - | -$10.68 M(+268.7%) | -$29.75 M(-7.2%) |
| Mar 2011 | - | -$2.90 M(-61.8%) | -$32.07 M(-312.4%) |
| Dec 2010 | $15.10 M(-132.3%) | -$7.59 M(-11.5%) | $15.10 M(+28.5%) |
| Sep 2010 | - | -$8.58 M(-34.0%) | $11.75 M(+57.5%) |
| Jun 2010 | - | -$13.00 M(-129.4%) | $7.46 M(-18.2%) |
| Mar 2010 | - | $44.27 M(-504.7%) | $9.13 M(-119.5%) |
| Dec 2009 | -$46.68 M(-14.3%) | -$10.94 M(-15.0%) | -$46.68 M(-6.4%) |
| Sep 2009 | - | -$12.87 M(+13.5%) | -$49.88 M(+0.8%) |
| Jun 2009 | - | -$11.34 M(-1.8%) | -$49.51 M(-5.0%) |
| Mar 2009 | - | -$11.54 M(-18.4%) | -$52.11 M(-4.4%) |
| Dec 2008 | -$54.48 M(+19.7%) | -$14.14 M(+13.2%) | -$54.48 M(+0.5%) |
| Sep 2008 | - | -$12.49 M(-10.4%) | -$54.23 M(+1.9%) |
| Jun 2008 | - | -$13.94 M(+0.2%) | -$53.21 M(+6.8%) |
| Mar 2008 | - | -$13.91 M(+0.2%) | -$49.84 M(+9.5%) |
| Dec 2007 | -$45.50 M(+18.1%) | -$13.88 M(+20.9%) | -$45.50 M(+22.0%) |
| Sep 2007 | - | -$11.48 M(+8.6%) | -$37.28 M(-0.1%) |
| Jun 2007 | - | -$10.57 M(+10.3%) | -$37.33 M(-0.3%) |
| Mar 2007 | - | -$9.58 M(+69.3%) | -$37.45 M(-2.8%) |
| Dec 2006 | -$38.52 M(-0.1%) | -$5.66 M(-50.9%) | -$38.52 M(-6.9%) |
| Sep 2006 | - | -$11.53 M(+7.9%) | -$41.35 M(+3.1%) |
| Jun 2006 | - | -$10.68 M(+0.3%) | -$40.11 M(+0.8%) |
| Mar 2006 | - | -$10.65 M(+25.4%) | -$39.80 M(+3.2%) |
| Dec 2005 | -$38.56 M(+65.5%) | -$8.49 M(-17.4%) | -$38.56 M(+3.5%) |
| Sep 2005 | - | -$10.29 M(-0.8%) | -$37.26 M(+15.1%) |
| Jun 2005 | - | -$10.37 M(+10.3%) | -$32.37 M(+21.1%) |
| Mar 2005 | - | -$9.40 M(+30.7%) | -$26.73 M(+14.7%) |
| Dec 2004 | -$23.29 M(+62.5%) | -$7.20 M(+33.4%) | -$23.29 M(+12.5%) |
| Sep 2004 | - | -$5.39 M(+14.0%) | -$20.71 M(+10.4%) |
| Jun 2004 | - | -$4.73 M(-20.8%) | -$18.75 M(+7.2%) |
| Mar 2004 | - | -$5.97 M(+29.5%) | -$17.50 M(+22.0%) |
| Dec 2003 | -$14.34 M(+19.3%) | -$4.61 M(+34.2%) | -$14.34 M(+47.4%) |
| Sep 2003 | - | -$3.44 M(-1.2%) | -$9.73 M(+54.7%) |
| Jun 2003 | - | -$3.48 M(+23.8%) | -$6.29 M(+123.8%) |
| Mar 2003 | - | -$2.81 M | -$2.81 M |
| Dec 2002 | -$12.02 M(+47.6%) | - | - |
| Dec 2001 | -$8.15 M(+105.6%) | - | - |
| Dec 2000 | -$3.96 M(+383.8%) | - | - |
| Dec 1999 | -$819.00 K | - | - |
FAQ
- What is Oncternal Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual EBIT year-on-year change?
- What is Oncternal Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly EBIT year-on-year change?
- What is Oncternal Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Oncternal Therapeutics?
- What is Oncternal Therapeutics TTM EBIT year-on-year change?
What is Oncternal Therapeutics annual earnings before interest & taxes?
The current annual EBIT of ONCT is -$41.71 M
What is the all time high annual EBIT for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual earnings before interest & taxes is $15.10 M
What is Oncternal Therapeutics annual EBIT year-on-year change?
Over the past year, ONCT annual earnings before interest & taxes has changed by +$3.23 M (+7.19%)
What is Oncternal Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of ONCT is -$8.68 M
What is the all time high quarterly EBIT for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly earnings before interest & taxes is $44.27 M
What is Oncternal Therapeutics quarterly EBIT year-on-year change?
Over the past year, ONCT quarterly earnings before interest & taxes has changed by +$98.00 K (+1.12%)
What is Oncternal Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of ONCT is -$35.96 M
What is the all time high TTM EBIT for Oncternal Therapeutics?
Oncternal Therapeutics all-time high TTM earnings before interest & taxes is $15.10 M
What is Oncternal Therapeutics TTM EBIT year-on-year change?
Over the past year, ONCT TTM earnings before interest & taxes has changed by +$2.39 M (+6.23%)